P

Inventor

BOSSART MARTIN

DE20 patents
⚠️ This page may combine multiple inventors who share the name “BOSSART MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SANOFI SA

14 patents
US9365632B2Jun 14, 2016

Exendin-4 derivatives as dual GLP1/glucagon agonists

SANOFI SA9 citations84
US9694053B2Jul 4, 2017

Dual GLP-1/glucagon receptor agonists

SANOFI SA4 citations73
US10538567B2Jan 21, 2020

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

SANOFI SA2 citations72
US10519211B2Dec 31, 2019

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

SANOFI SA2 citations72
US9982029B2May 29, 2018

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

SANOFI SA2 citations72
US9775904B2Oct 3, 2017

Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists

SANOFI SA4 citations72
US9771406B2Sep 26, 2017

Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4

SANOFI SA4 citations72
US9758561B2Sep 12, 2017

Dual GLP-1/glucagon receptor agonists derived from exendin-4

SANOFI SA6 citations72
US11141489B2Oct 12, 2021

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

SANOFI SA0 citations58
US10792367B2Oct 6, 2020

Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid

SANOFI SA1 citations58
US10758592B2Sep 1, 2020

Exendin-4 derivatives as dual GLP1/glucagon agonists

SANOFI SA0 citations52
US9221784B2Dec 29, 2015

Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists

SANOFI SA1 citations51
US11352405B2Jun 7, 2022

GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

SANOFI SA0 citations45
US10806797B2Oct 20, 2020

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

SANOFI SA0 citations39

SANOFI AVENTIS DEUTSCHLAND

3 patents

SCHWINK LOTHAR

1 patent

ANTAROS MEDICAL AB

1 patent

AVENTIS PHARMA SA

1 patent